Duration: 02:19

Biological E Vaccine completes its clinical trials and has received approval to start Phase-3 trials in India.Biological E Limited (BE) has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India with promising results and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organisation (CDSCO) – Subject Expert Committee (SEC). BE started the Phase I/II clinical trials of its COVID-19 Vaccine candidate in the second week of November 2020, the vaccine maker said in a press release.The Phase III clinical study will be conducted in 15 sites across India and it will evaluate the immunogenicity and safety of Biological E’s SARS-CoV-2 COVID-19 vaccine for protection against the disease in about 1,268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study.BE’s vaccine candidate includes an antigen developed by the Texas Children’s Hospital Center for Vaccine Development and in- licensed from BCM Ventures, Baylor College of Medicines integrated commercialization team, along with Dynavax Technologies Corporations advanced adjuvant CpG 1018TM. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Biotechnology Industry Research Assistance Council (BIRAC) have provided support for the Phase I/II clinical trials and also for the upcoming Phase III trial of this vaccine candidate, it said.#CovidInIndia #CovidUpdates #CovidCrisisSubscribe to our channel for the latest news updates: http://bit.ly/2KGXvAW#GetCloserToTheNews with latest headlines on politics, sports, and entertainment on https://bit.ly/2Y4QccLTo stay updated on-the-go, download the News18 App: · Google Play Store: http://bit.ly/2VcRTRc· Apple App Store: https://apple.co/2JceAmY Follow us for latest news, photos & videos:· Facebook: http://bit.ly/2vOO22u· Twitter: http://bit.ly/2HdNKch· Instagram: http://bit.ly/2PRgfiz. Telegram: https://bit.ly/2ZOalG0CNN-News18 is India’s most awarded English News Channel and is one of the most respected and dynamic media brands in the country today. CNN-News18 has in a short time, redefined the limits and has set new standards for journalism in Indian news television through its differentiated programming and philosophy of inclusive journalism the spirit of ‘Whatever It Takes’. CNN-News18 continues to be India’s window to the world and the world’s window into India. CNN-News18 has been awarded all the prestigious awards in the General News category in the country.